Allarity Therapeutics Inc. Common Stock (ALLR)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I look first for durable earning power and a margin of safety. Allarity fails both tests today. It is a clinical-stage cancer company with a lead candidate, stenoparib, and a DRP platform, but in fiscal Q1 2026, the quarter ended 2026-03-31, revenue was only $25,000 and net loss was $2.8 million. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss widened to $3.4 million. For FY2025, ended 2025-12-31, revenue was $320,000 and net loss was $11.2 million, or diluted EPS -$0.78; FY2024, ended 2024-12-31, had no revenue and a $24.5 million net loss. The improvement in annual loss is encouraging, but there is still no profit. Financial health is poor: trailing free cash flow is -$13.8 million, a FairStock-calculated FCF yield of -99.6%; debt-to-equity is 6.30; Altman Z-Score is -5.81; Piotroski F-Score is 3/9. At the 2026-10-13 close of $0.87, FairStock figures show P/B 3.95 and P/E -1.10. The market cap of $13.8 million roughly equals one year of cash burn. There is no demonstrated moat, only speculative clinical optionality. FairStock assigns no Lynch category because it has lost money in each of the last four years. I would need much clearer evidence of commercial viability and a much stronger balance sheet before calling this anything but speculative.

In plain English: Allarity Therapeutics is a tiny experimental cancer drug company with seven employees. It has almost no revenue and has lost money in each of the last four years, with recent quarterly losses of $2.8 million to $3.4 million. At $0.87 on 2026-10-13, the stock is near the low end of its 52-week range, but the business earns very little and keeps losing money, so the price looks expensive compared with current results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer